BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 9, 2006
View Archived Issues
Indian approval for phase II study of crofelemer in acute infectious diarrhea
Read More
MAP-0010 studied for asthma in new phase II trial
Read More
BDSI acquires non-U.S. BEMA rights, licenses BEMA Fentanyl to Meda for Europe
Read More
Antitumor activity of a novel lignan isolated from Chinese herbal medicine
Read More
Amorfix Life Sciences and Biogen Idec to collaborate in ALS
Read More
Icagen implements DMC's recommendations in phase III study of ICA-17043
Read More
SPA for pivotal study of Fodosine in T-cell leukemia
Read More
Allon seeks clearance to add Canadian sites to phase II study of AL-208
Read More
Arpida cleared for U.K. microdose study of AR-709
Read More
Phase I study for NGX-426, oral prodrug of tezampanel
Read More
Phase II study of INS-50589 Antiplatelet terminated after bleeding complications
Read More
PRX-08066 studied for pulmonary hypertension associated with COPD
Read More
Fast track designation for NOV-002 in NSCLC
Read More
Diamyd sublicenses use of GAD65 gene to Neurologix for Parkinson's disease
Read More
European submission for Avastin in NSCLC
Read More
Inflammatory bowel disease compound NV-52 continues phase I testing
Read More
HCV-I.E.T. shows signs of efficacy in HCV nonresponders
Read More
TopoTarget's post-extravasation drug approved in Europe, approvable in U.S.
Read More
New compounds targeting cardiovascular diseases disclosed in recent patent literature
Read More
Mexico first to approve Januvia
Read More
Allergan patents novel prostanoid EP2 agonists for glaucoma
Read More
Recent patents disclose new agents for arthritis, autoimmune disorders, etc.
Read More
Promising antitumor activity of novel photodynamic agents
Read More
Novel PARP-1 inhibitor protects Huntington's disease cells from oxidative damage in vitro
Read More
Blocking adenosine A2B receptor with CVT-6883 reduces pulmonary inflammation and injury in vivo
Read More